• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AVLN
Held by 1 Guru
Share

Avalyn Pharma Inc. Stocks

$ 34.71Last Updated 16.09.2026

Issuer Rating

2/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 1.52B

$ 34.71
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

03.05.2026 21:00

S&P goes after SpaceX, Uzbekistan fund to offer discount: the main thing about the IPO by Ma. 3

30.04.2026 15:00

Avalyn Pharma IPO: Novo Nordisk-backed biotech goes public

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of AVLN is 57.3 and suggests 65% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.09.2026 22:54

Lucid has decided to launch 25,000 robotaxis in Europe in partnership with Bolt. Its stock soared.

17.09.2026 22:00

Nuclear energy company Holtec has suspended its IPO. Why is this important for AI investors?

17.09.2026 21:55

How Could the Revolut Data Breach Have Been Avoided? A Financial Crime Expert Weighs In

17.09.2026 21:41

The SEC has authorized trading of tokenized stocks in the U.S. What does this mean?

17.09.2026 20:43

Revolut Is Aiming for a Dual Listing in New York and London — Staronsky

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026